Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial

scientific article published on 07 March 2019

Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/CAM4.2042
P932PMC publication ID6488147
P698PubMed publication ID30843659

P50authorDavid E SpanerQ92186816
P2093author name stringYonghong Shi
Hubert Tsui
Lindsay McCaw
Guizhei Wang
P2860cites workGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesQ24616084
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient dataQ31096565
Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: evidence for decreased platelet productionQ33335197
Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice, (NZW x BXSB) F1Q33374619
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisQ33399980
Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesisQ33417004
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b studyQ33437373
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trialQ33438420
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinibQ35450520
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participantsQ35822277
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells.Q36118340
Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedbackQ36238033
β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemiaQ36743899
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II StudyQ36759124
Dose escalation methods in phase I cancer clinical trialsQ37198192
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cellsQ37209768
Assessing splenomegaly: automated volumetric analysis of the spleenQ37622042
Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signalingQ38069567
Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseasesQ38159870
Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A.Q38867757
miR141-CXCL1-CXCR2 signaling-induced Treg recruitment regulates metastases and survival of non-small cell lung cancerQ38944644
Identification of the cytoplasmic domains of CXCR4 involved in Jak2 and STAT3 phosphorylation.Q40477812
Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trialQ42399878
Ibrutinib treatment improves T cell number and function in CLL patientsQ42909982
Ibrutinib-resistant CLL: unwanted and unwonted!Q48114125
Life after ibrutinib? A new unmet need in CLL.Q48210951
IL-4 enhances expression and function of surface IgM in CLL cells.Q55026394
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemiaQ57169180
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinibQ58593499
In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO)Q68707975
Recombinant PDGF enhances megakaryocytopoiesis in vitroQ70861840
Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosisQ77768132
The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentQ78846264
Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemiaQ83128977
Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cellsQ91272438
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectchronic lymphocytic leukemiaQ1088156
phase I clinical trialQ5452194
ibrutinibQ5984881
platelet formationQ14914622
P304page(s)1540-1550
P577publication date2019-03-07
P1433published inCancer MedicineQ27724564
P1476titlePersistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial
P478volume8

Search more.